Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis

Critical Reviews in Microbiology

Volumn 41, Issue 1, 2015, Pages 124-134

  Heng, Siow Chin ^a   Morrissey, Orla ^b   Chen, Sharon C A ^c   Thursky, Karin ^d   Manser, Renee L ^d   Nation, Roger L ^a   Kong, David C M ^a   Slavin, Monica ^d  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HEALTH   (Australia)

^c Westmead Hospital   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Aspergillosis; BAL galactomannan; Hematology; Meta analysis

Indexed keywords

ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; GALACTOMANNAN; MANNAN;

BRONCHOSCOPY; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; HEMATOLOGIC MALIGNANCY; HUMAN; INVASIVE ASPERGILLOSIS; LUNG INFILTRATE; LUNG LAVAGE; META ANALYSIS; NOMOGRAM; OPTICAL DENSITY; OPTICAL DENSITY INDEX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADULT; ASPERGILLOSIS; BLOOD; CHEMISTRY; COMPLICATION; HEMATOLOGIC DISEASE; METABOLISM; MICROBIOLOGY; PROCEDURES;

ASPERGILLUS;

ADULT; ASPERGILLOSIS; BRONCHOALVEOLAR LAVAGE FLUID; HEMATOLOGIC NEOPLASMS; HUMANS; MANNANS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84921752648     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2013.804033     Document Type: Review

References (76)

1. Adam O, Auperin A, Wilquin F, et al. (2004). Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38:917-20.
2. Ascioglu S, Rex JH, de Pauw B, et al. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14.
3. Balloy V, Huerre M, Latge JP, Chignard M. (2005). Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 73:494-503.
4. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. (2003). Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 121:448-57.
5. Berenguer J, Allende MC, Lee JW, et al. (1995). Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 152:1079-86.
6. Bergeron A, Belle A, Sulahian A, et al. (2010). Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 137:410-5.
7. Bergeron A, Porcher R, Menotti J, et al. (2012). Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 50:823-30.
8. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. (2010). False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 42:461-8.
9. Boselli E, Breilh D, Cannesson M, et al. (2004). Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976-9.
10. Bossuyt PM, Reitsma JB, Bruns DE, et al. (2003). Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326:41-4.
11. Buchheidt D, Hummel M, Schleiermacher D, et al. (2004). Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 125:196-202.
12. Cummings JR, Jamison GR, Boudreaux JW, et al. (2007). Cross-reactivity of non- Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 59:113-5.
13. D'Haese J, Theunissen K, Vermeulen E, et al. (2012). Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 50:1258-63.
14. Danpornprasert P, Foongladda S, Tscheikuna J. (2010). Impact of bronchoalveolar lavage galactomannan on the outcome of patients at risk for invasive pulmonary aspergillosis. J Med Assoc Thai 93:S86-93.
15. De Pauw B, Walsh TJ, Donnelly JP, et al. (2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-21.
16. Deeks JJ. (2001). Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 323:157-62.
17. Deeks JJ, Macaskill P, Irwig L. (2005). The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882-93.
18. Desai R, Ross LA, Hoffman JA. (2009). The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 28:283-6.
19. Donnelly JP. (2010). Defining invasive aspergillosis: what the revised EORTC/MSG definitions have in store. In: Pasqualotto AC, ed. Aspergillosis: From Diagnosis to Prevention. New York: Springer, 423-35.
20. Dwamena Ben A. (2009). Midas: Stata module for meta-analytical integration of diagnostic test accuracy studies [Online]. Ann Arbor, MI: Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School.
21. Fagan TJ. (1975). Letter: Nomogram for Bayes theorem. N Engl J Med 293:257.
22. Florent M, Katsahian S, Vekhoff A, et al. (2006). Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 193:741-7.
23. Francesconi A, Kasai M, Petraitiene R, et al. (2006). Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 44:2475-80.
24. Frealle E, Decrucq K, Botterel F, et al. (2009). Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance. Eur J Clin Microbiol Infect Dis 28:223-32.
25. Gerlinger MP, Rousselot P, Rigaudeau S, et al. (2012). False positive galactomannan Platelia due to piperacillin-tazobactam. Med Mal Infect 42:10-4.
26. Glas AS, Lijmer JG, Prins MH, et al. (2003). The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129-35.
27. Guo YL, Chen YQ, Wang K, et al. (2010). Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 138:817-24.
28. Hachem RY, Kontoyiannis DP, Chemaly RF, et al. (2009). Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47:129-33.
29. Hadrich I, Makni F, Cheikhrouhou F, et al. (2012). Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis. Pathol Biol (Paris) 60:357-61.
30. Hadrich I, Mary C, Makni F, et al. (2011). Comparison of PCR-ELISA and Real-Time PCR for invasive aspergillosis diagnosis in patients with hematological malignancies. Med Mycol 49:489-94.
31. Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a metaanalysis. Stat Med 21:1539-58.
32. Hope WW, Kruhlak MJ, Lyman CA, et al. (2007). Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 195:455-66.
33. Hsu LY, Ding Y, Phua J, et al. (2010). Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect Dis 10:44.
34. Jaeschke RZ, Guyatt GH, Sackett DL. (1994). Users' guides to the medical literature: III. How to use an article about a diagnostic test: B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271:703-7.
35. Kami M, Fukui T, Ogawa S, et al. (2001). Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 33:1504-12.
36. Kappe R, Schulze-Berge A. (1993). New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol 31:2489-90.
37. Kimura S, Odawara J, Aoki T, et al. (2009). Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients. Int J Hematol 90:463-70.
38. Kontoyiannis DP, Marr KA, Park BJ, et al. (2010). Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091-100.
39. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. (2008). Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev, CD007394.
40. Lijmer JG, Bossuyt PM, Heisterkamp SH. (2002). Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21:1525-37.
41. Luong ML, Filion C, Labbe AC, et al. (2010). Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 68:132-9.
42. Maertens J, Maertens V, Theunissen K, et al. (2009). Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 49:1688-93.
43. Marr KA, Balajee SA, McLaughlin L, et al. (2004). Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190:641-9.
44. Marr KA, Laverdiere M, Gugel A, Leisenring W. (2005). Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40:1762-9.
45. Maschmeyer G. (2011). Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic cancer patients. Curr Infect Dis Rep 13:510-6.
46. Mennink-Kersten MA, Donnelly JP, Verweij PE. (2004). Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4:349-57.
47. Mennink-Kersten MA, Ruegebrink D, Wasei N, et al. (2006). In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 44:1711-8.
48. Mikulska M, Furfaro E, Del Bono V, et al. (2012). Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for falsepositive results of the galactomannan assay. J Antimicrob Chemother 67:1746-8.
49. Millon L, Piarroux R, Deconinck E, et al. (2005). Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol 43:5097-101.
50. Musher B, Fredricks D, Leisenring W, et al. (2004). Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 42:5517-22.
51. Narreddy S, Chandrasekar PH. (2008). False-positive Aspergillus galactomannan (GM) assay in histoplasmosis. J Infect 56:80-1.
52. Nguyen MH, Leather H, Clancy CJ, et al. (2011). Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 17:1043-50.
53. Pagano L, Caira M, Candoni A, et al. (2010). Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95:644-50.
54. Park SY, Lee SO, Choi SH, et al. (2010). Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 61:492-8.
55. Penack O, Rempf P, Graf B, et al. (2008). Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol 19:984-9.
56. Petitti DB. (2001). Approaches to heterogeneity in meta-analysis. Stat Med 20:3625-33.
57. Pfeiffer CD, Fine JP, Safdar N. (2006). Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42:1417-27.
58. Racil Z, Kocmanova I, Toskova M, et al. (2011). Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 15:e874-81.
59. Reinwald M, Spiess B, Heinz WJ, et al. (2012). Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 89:120-7.
60. Reitsma JB, Glas AS, Rutjes AW, et al. (2005). Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58:982-90.
61. Rimek D, Zimmermann T, Hartmann M, et al. (1999). Disseminated Penicillium marneffei infection in an HIV-positive female from Thailand in Germany. Mycoses 42:25-8.
62. Sanguinetti M, Posteraro B, Pagano L, et al. (2003). Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 41:3922-5.
63. Scotter JM, Campbell P, Anderson TP, et al. (2005). Comparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. Pathology 37:246-53.
64. Stephens-Romero SD, Mednick AJ, Feldmesser M. (2005). The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect Immun 73:114-25.
65. Sulahian A, Touratier S, Ribaud P. (2003). False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 349:2366-7.
66. Sun W, Wang K, Gao W, et al. (2011). Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate metaanalysis and systematic review. PLoS One 6:e28467.
67. Swanink CM, Meis JF, Rijs AJ, et al. (1997). Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 35:257-60.
68. Swets JA. (1988). Measuring the accuracy of diagnostic systems. Science 240:1285-93.
69. Torelli R, Sanguinetti M, Moody A, et al. (2011). Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 49:4273-8.
70. Tortorano AM, Esposto MC, Prigitano A, et al. (2012). Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 50:1051-3.
71. Verweij PE, Latge JP, Rijs AJ, et al. (1995). Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J Clin Microbiol 33:3150-3.
72. Viscoli C, Machetti M, Cappellano P, et al. (2004). False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 38:913-6.
73. Walsh TJ, Shoham S, Petraitiene R, et al. (2004). Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 42:4744-8.
74. Wheat LJ, Hackett E, Durkin M, et al. (2007). Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 14:638-40.
75. Whiting PF, Rutjes AW, Westwood ME, et al. (2011). QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529-36.
76. Zou M, Tang L, Zhao S, et al. (2012). Systematic review and metaanalysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 7:e43347.